Andrew M. Jones

United Kingdom

Poster(s):

• (20) Impact of Elexacaftor/Tezacaftor/Ivacaftor therapy on older patients with Cystic Fibrosis
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (89) A Novel CF-Pregnancy Service: Two year review following introduction of elexacaftor/tezacaftor/ivacaftor (Kaftrio)
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (205) Do we need a colorectal cancer screening programme for patients with cystic fibrosis?
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (220) Changes in Liver Function Tests and Liver Stiffness Measurements over 12 months in Cystic Fibrosis Patients commenced on Elexacaftor/Tezacaftor/Ivacaftor at a Large Adult Center
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (495) Identification of airway Aspergillus fumigatus infection – use of cough swabs is not a suitable alternative to fungal sputum culture
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET